曲匹地尔在心血管系统中的药理作用和临床研究进展  

Trapidil's Pharmacological Effects in Cardiovascular System and Its Clinical Research Progress

作　　者：王炎[1] 丁虎[1] 严江涛[1] 曾和松[1] 汪道文[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院心内科,湖北武汉430030

出　　处：《心血管病学进展》2013年第5期710-713,共4页Advances in Cardiovascular Diseases

摘　　要：近年来多项心血管药物的临床试验未能获预期结果,而曲匹地尔独特的多靶向心血管作用,提示其潜在的临床价值。曲匹地尔改善心绞痛显著优于硝酸异山梨酯,在冠状动脉病变患者较阿司匹林可显著减少总的心血管事件,支架植入术后不能耐受阿司匹林者可换用曲匹地尔,目前上述临床效应尚缺乏多中心、随机、双盲对照研究证实。近期开展的相关大型临床试验,包括曲匹地尔的药物支架试验,冠状动脉粥样硬化性心脏病一级、二级预防试验有希望揭示其在心血管疾病中的价值。In the past decade, multiple cardiovascular drugs failed to achieve their goals in clinical trials. Thus, trapidil, a unique cardiovascular drug with multi-target roles, may be prospective. The present data suggests that trapidil excels isosorbide dinitrate in relieving angina pectoris, and apparently outdoes aspirin in reducing the total cardiovascular events, and it can be a substitute for aspirin if the patients intolerant with aspirin. Anyway, those effects need to be confirmed by further randomized double-blind clinical trials. Large clinical trials being carried in the near future including trapidil-elute stent, primary, and secondary prevention trials in coronary artery disease may reveal the value of this drug.

关 键 词：曲匹地尔 动脉粥样硬化 血栓 心绞痛 

分 类 号：R96[医药卫生—药理学]